{
    "brief_title": "ARX788 in Breast Cancer With Low Expression of HER2",
    "phase": "Phase 2",
    "drugs": "['ARX788']",
    "drugs_list": [
        "ARX788"
    ],
    "diseases": "['Breast Cancer With Low Expression of HER2']",
    "diseases_list": [
        "Breast Cancer With Low Expression of HER2"
    ],
    "enrollment": "54.0",
    "inclusion_criteria": "inclusion criteria: \n\n Willing and able to understand and sign an informed consent inform; \n\n Age \u226518 years, and \u226475 years, male or female; \n\n Diagnosed as HR arbitrary/HER2 low expression unresectable and/or metastatic breast cancer. HER2 low expression is defined as HER2 IHC 1+ (FISH negative or FISH not done) or HER2 IHC 2+ and FISH negative; \n\n Received \u22652 lines of systemic chemotherapy regimens for recurrent or metastatic disease, and for HR positive subjects, also need to have received \u22652-line endocrine therapy \u00b1 targeted therapy (including neoadjuvant/adjuvant therapy); \n\n Never had a HER2 positive result (IHC 3+ or FISH+) in previous pathological examinations; \n\n Have archived or fresh tumor tissue samples for HER2 status confirmation; \n\n According to the RECIST 1.1 standard, there is at least one measurable lesion; \n\n Eastern Cooperative Oncology Group (ECOG) performance status of 0 or1; LVEF\u226550%; \n\n Adequate organ functions; \n\n Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade \u22641; \n\n Life expectancy \u2265 3 months. \n\n ",
    "exclusion_criteria": ": \n\n History of allergic reactions to any component of ARX788, or with a history of protein drug allergy, a history of specific allergies (asthma, rheumatism, eczematous dermatitis), or a history of other severe allergic reactions, who are unsuitable for ARX788 treatment as per the investigator's judgments; \n\n Previous treatment with T-DM1 or other HER2-ADC drugs; \n\n Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured); \n\n Have primary central nervous system (CNS) tumors or CNS metastases; \n\n Prior history of interstitial pulmonary disease requiring hormone therapy, drug-induced interstitial pulmonary disease, radiation pneumonia, or current clinically active interstitial pulmonary disease; \n\n Suffering from keratitis, corneal diseases, retinal diseases or active eye infections that require intervention; \n\n Unwilling or unable to stop wearing contact lenses for the duration of the study; \n\n Cardiac insufficiency; \n\n Uncontrolled hypertension; \n\n Suffering severe or uncontrolled systemic diseases; \n\n Had chemotherapy, radiotherapy, or immunotherapy within 4 weeks before the first dose; \n\n Had breast cancer endocrine therapy within 2 weeks before the first dose; \n\n Had palliative radiotherapy for bone metastasis within 2 weeks before the first dose; \n\n Any uncontrolled infection, or other conditions that may limit trial compliance or interfere with evaluation; \n\n Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus or syphilis; \n\n Plan to receive major surgical treatment within 2 weeks before first dose or during the trial period, or have suffered severe traumatic injury; \n\n Pregnancy or lactation; \n\n Unwilling or unable to use acceptable methods for contraception during the entire treatment period of this trial and within 8 months after the last dose; \n\n Participated in other clinical trials and used other experimental drugs within 4 weeks before the first dose; \n\n Any mental or cognitive impairment may limit their understanding and implementation of the informed consent form; \n\n Not suitable for participating in this trial, such as poor compliance.",
    "brief_summary": "A Phase 2 Study of ARX788 in unresectable and/or metastatic breast cancer with low expression of HER2.",
    "NCT_ID": "NCT05018676"
}